作者
Nadera J Sweiss, Peter Korsten, Huzaefah J Syed, Aamer Syed, Robert P Baughman, Arthur MF Yee, Daniel A Culver, Teresa Sosenko, Arata Azuma, Francesco Bonella, Ulrich Costabel, Wonder P Drake, Marjolein Drent, Elyse E Lower, Dominique Israel-Biet, Remy LM Mostard, Hilario Nunes, Paola Rottoli, Paolo Spagnolo, Athol U Wells, Wim A Wuyts, Marc A Judson
发表日期
2020/9/1
期刊
Chest
卷号
158
期号
3
页码范围
892-895
出版商
Elsevier
简介
Over the past few months, the novel coronavirus disease 2019 (COVID-19) pandemic has posed many challenges for practicing physicians. Patients with sarcoidosis may have an increased risk of a poor outcome and death from COVID-19 infection for several reasons. First, sarcoidosis involves the lung in approximately 90% of patients, 1 many of whom have diminished baseline lung function with reduced pulmonary reserve should they develop respiratory failure. Second, although the etiology of sarcoidosis is unknown, it is postulated that immunologic dysfunction and dysregulation play essential roles in the development of the disease. 2 Third, African-American race and many comorbidities
ABBREVIATIONS: ADA= adalimumab; COVID-19= coronavirus disease 2019; DMASD= disease-modifying antisarcoid drug; GC= glucocorticoid
学术搜索中的文章
NJ Sweiss, P Korsten, HJ Syed, A Syed, RP Baughman… - Chest, 2020